Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Revvity Inc — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.16 (market cap $28.69M), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 591.8× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Revvity Inc pays a 0.18% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 61 Days and Revvity Inc for 12 Days on average.
| QDTY | RVTY | |
|---|---|---|
Market Cap | $28.69M | $16.98B |
Volume | 22,490 | 1,456,900 |
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $157.36 |
52-Week Low | $36.57 | $82.26 |
Typical Hold Time | 61 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $39.27, down 0.84% today, with a bullish technical signal supported by moving averages. The ETF demonstrates strong dividend distribution activity with recent payouts ranging from $0.19 to $0.30 per share, highlighted by a $0.24 dividend announced October 6th, 2026 representing a significant yield. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while overall trend remains positive.
The outlook remains favorable for income-focused investors given the consistent dividend payments, though elevated RSI levels suggest near-term caution. Key risks include market volatility affecting covered call strategies and interest rate sensitivity. The ETF's weekly distribution model provides regular income but requires monitoring of underlying Nasdaq 100 performance for sustainability.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
